Recombinant human erythropoietins

What are Recombinant human erythropoietins?

Recombinant human erythropoietins, act like endogenous erythropoietin to stimulate erythropoiesis, the process of red blood cell production. Endogenous erythropoietin is a hormone that is secreted by particular cells in the kidneys in response to reduced levels of oxygen reaching the tissues in the kidneys.

Recombinant human erythropoietins are given to patients with kidney failure to treat anemia.

Recombinant human erythropoietin (rHuEPO) is a biopharmaceutical drug given to patients who have a low hemoglobin related to chronic kidney disease, cancer or anemia.

Erythropoietin (EPO) interacts directly with the EPO receptor on the red blood cell (RBC) surface, triggering activation of several signal transduction pathways, resulting in the proliferation and terminal differentiation of erythroid precursor cells and providing protection from RBC precursor apoptosis.

The production of recombinant human erythropoietin (r-HuEPO) began with a search for the gene coding for human erythropoietin (EPO). Two radiolabeled pools of oligonucleotide probes were designed, based on amino acid sequence information obtained from human urinary EPO.

This review describes some of the physiological effects of recombinant human erythropoietin (EPO) in healthy humans. At the blood level EPO increases the arterial O₂content not only by increasing red blood cell volume, but also by an equally important decrease in plasma volume.

Recombinant Hb (r Hb 1.1) is a method in which a few parts of an amino acid sequence of human Hb are replaced to prevent the dissociation into dimers and to maintain adequate oxygen affinity.